ECU
ASND icon

Eisler Capital (US)’s Ascendis Pharma A/S ASND Stock Holding History

Eisler Capital (US)’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,080
Closed -$829K – 489
2024
Q2 		$829K Buy
+6,080
New +$827K 0.01% 492

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Eisler Capital (US)'s ASND Position: Q3 2024 in Review

Eisler Capital (US) sold out of Ascendis Pharma A/S (ASND) in Q3 2024, closing a stake of 6,080 shares — an estimated $829K sold.

Eisler Capital (US) first reported a position in ASND in Q2 2024 and held it in 1 quarter. The position peaked at $829K in Q2 2024. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

  • Eisler Capital (US) reported no remaining Ascendis Pharma A/S position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 6,080 Ascendis Pharma A/S shares in Q3 2024, an estimated $829K.
  • Eisler Capital (US) first reported a position in Ascendis Pharma A/S in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Ascendis Pharma A/S position peaked at $829K in Q2 2024.
  • 219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.